Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Disease Biology

Approaching patients with FLT3-mutated AML who are ineligible for high-intensity chemotherapy 2:12
Approaching patients with FLT3-mutated AML who are ineligible for high-intensity chemotherapy
Andrius Žučenka • 8 Dec 2023
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion 1:53
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion
Giada Bianchi • 29 Sep 2023
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma 1:48
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma
Giada Bianchi • 29 Sep 2023
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14) 1:46
Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)
Gareth Morgan • 29 Sep 2023
Highlights from IMS 2023: integrating multi-omic technologies & understanding resistance 1:40
Highlights from IMS 2023: integrating multi-omic technologies & understanding resistance
Constantine Mitsiades • 29 Sep 2023
Using CRISPR technology to identify genes preferentially essential for multiple myeloma cells 1:37
Using CRISPR technology to identify genes preferentially essential for multiple myeloma cells
Constantine Mitsiades • 29 Sep 2023
The impact of CHIP in patients with AL amyloidosis 1:52
The impact of CHIP in patients with AL amyloidosis
Giada Bianchi • 29 Sep 2023
Addressing proteasome inhibitor resistance in multiple myeloma in the immunotherapy era 1:37
Addressing proteasome inhibitor resistance in multiple myeloma in the immunotherapy era
Arun Wiita • 29 Sep 2023
New therapeutic targets in DLBCL
Ash Alizadeh et al. • 17 Oct 2023
13:01
Updates on the biology and treatment of T-cell lymphoma
Francine Foss et al. • 17 Oct 2023
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma 1:47
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma
Leo Rasche • 28 Sep 2023
The role of small nucleotide, copy number and structural variants in extramedullary myeloma 2:00
The role of small nucleotide, copy number and structural variants in extramedullary myeloma
Nicholas Bingham • 28 Sep 2023
Highlights of IMS 2023: the origins of myeloma and the role of the microenvironment 2:08
Highlights of IMS 2023: the origins of myeloma and the role of the microenvironment
Wee Joo Chng • 29 Sep 2023
The genetic landscape of MDS: how this is improving & impacting the development of therapies 3:36
The genetic landscape of MDS: how this is improving & impacting the development of therapies
Jan Bewersdorf • 6 Oct 2023
Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma 8:06
Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma
Marios Papadimitriou • 29 Sep 2023
Diagnosis and potential therapeutic options for AA amyloidosis 1:51
Diagnosis and potential therapeutic options for AA amyloidosis
Nelson Leung • 28 Sep 2023
The content of VJHemOnc is intended for healthcare professionals